We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Apenas manchetes de alto sinal — eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
A number of stocks fell in the morning session after the April PPI report sent Treasury yields to 10-month highs, with the 10-year yield rising to 4.49%.
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Doximity (DOCS) delivered earnings and revenue surprises of -7.14% and +1.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
The fair value estimate for Veeva Systems sits at US$264.46, holding steady even as the broader software sector sees shifting valuations. Analysts link this unchanged target to a mix of confidence in Veeva's recent Q4 execution and caution around longer term questions on AI, R&D growth, and CRM commitments. As you read on, you will see how these competing views are shaping the evolving story around the stock and what signals to watch next. Stay updated as the Fair Value for Veeva Systems...
OPRX launched a programmatic EHR ad connection for DSPs, expanding point-of-care targeting and access to authenticated inventory.
Veeva Systems Inc. (NYSE:VEEV) is one of the best stocks to buy with wide moats. The latest moat-relevant update came on May 6, 2026, when Snowflake said it was collaborating with Veeva Systems Inc. (NYSE:VEEV) to connect the Snowflake AI Data Cloud for Healthcare & Life Sciences with the Veeva Vault Platform. The new Snowflake […]
HIMS first-quarter 2026 results are likely to benefit from Labs and branded weight loss medications even as higher costs and GLP-1 scrutiny linger.
Investors may be wondering whether Veeva Systems at about US$168.25 is starting to look interesting, or if the stock still carries too much optimism in its price. Over the last week the share price has moved by 7.9%, compared with a 2.5% decline over 30 days and deeper returns of 23.3% year to date and 29.8% over the past year. Recent coverage has focused on Veeva Systems as a key healthcare software provider, with attention on how its role in life sciences workflows might affect sentiment...
Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In the closing of the recent trading day, Veeva Systems (VEEV) stood at $167.29, denoting a -2.28% move from the preceding trading day.
Veeva Systems, Doximity and Omnicell ride rising AI-driven healthcare demand as medical info systems expand despite cybersecurity and regulatory risks.
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.
Doximity, Veeva and Omnicell ride surging GenAI adoption in healthcare, tapping digital demand despite market pressure and rising cybersecurity risks.
According to the average brokerage recommendation (ABR), one should invest in Veeva (VEEV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
In April 2026, Veeva Systems Inc. announced that long-time Senior Vice President and General Counsel Josh Faddis will retire on November 1, 2026, transitioning to a part-time advisory role thereafter. Around the same time, Veeva revealed it will be added to the S&P 500 Index, a milestone that often broadens a company’s investor base and enhances trading liquidity. We’ll now explore how Veeva’s S&P 500 inclusion may influence its investment narrative built around AI integration and...